Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Therapeuticsmd Inc (NQ: TXMD )

1.730 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.730
Bid (Size) 1.600 (2)
Ask (Size) 1.900 (1)
Prev. Close 1.730
Today's Range 1.730 - 1.730
52wk Range 1.430 - 4.310
Shares Outstanding 9,953,290
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023
TherapeuticsMD just reported results for the fourth quarter of 2023. 
Via InvestorPlace
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024
TherapeuticsMD just reported results for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-25.75%
-25.75%
1 Month
+1.75%
+1.75%
3 Month
-14.78%
-14.78%
6 Month
-23.79%
-23.79%
1 Year
-58.01%
-58.01%

More News

Read More
TherapeuticsMD Announces First Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
TherapeuticsMD Announces Third Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Nasdaq Jumps 100 Points; US Trade Deficit Widens In September
Via Benzinga
Topics Stocks
Exposures US Equities
TherapeuticsMD Announces Second Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
TherapeuticsMD Announces First Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
From TherapeuticsMD, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Third Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Additional $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
From TherapeuticsMD, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.